<DOC>
	<DOCNO>NCT02489994</DOCNO>
	<brief_summary>Clinical Study Evaluate Performance ePrime System Treatment Cellulite .</brief_summary>
	<brief_title>Performance ePrime System Cellulite</brief_title>
	<detailed_description>Up 60 healthy adult volunteer seek cellulite treatment , females 25 60 year age , multiple investigational site . This open-label , multi-center study . Subjects study receive single subcutaneous treatment ePrime device one treatment session accord study protocol . Prior treatment , tissue treat injected tumescence local dermal infiltration solution accord protocol . Subjects return follow‐up ( FU ) visit : 1 week , 1 month , 3 month 6 month follow treatment . Methodology describe protocol evaluate efficacy treatment carry visit .</detailed_description>
	<criteria>1 . Subjects seek treatment cellulite upper thigh buttock area . 2 . Subject cellulite stage II III grade use NurnbergerMuller scale clasification ( Appendix III ) 3 . Healthy female subject age 25 60 year age 4 . Informed consent process complete subject sign consent 5 . Willing receive propose ePrime treatment followup protocol 6 . Not pregnant lactating must either postmenopausal , surgically sterilize , use medically acceptable form birth control least 3 month prior enrollment ( i.e. , oral contraceptive , contraceptive implant , barrier method spermicide abstinence ) 7 . Willing photograph take treated area use deidentified evaluation , publication presentation 1 . Subject surgery procedure cellulite last 6 month 2 . Pregnant plan become pregnant , give birth le 3 month ago , and/or breast feeding 3 . Known allergy lidocaine epinephrine antibiotic 4 . Active malignancy history malignancy past 5 year 5 . Having active electrical implant anywhere body , pacemaker internal defibrillator 6 . Suffering significant concurrent illness , cardiac disorder , diabetes ( type I II ) , lupus , porphyria , pertinent neurological disorder ( i.e . disease state opinion Physician would interfere anesthesia , treatment , heal process ) 7 . Having know anticoagulative thromboembolic condition take anticoagulation medication one week prior treatment course ( allow inclusion , temporary cessation use per subject 's physician discretion ) 8 . History immunosuppression/immune deficiency disorder ( include HIV infection AIDS ) currently use immunosuppressive medication 9 . Suffering hormonal imbalance , whether related thyroid , pituitary , androgen 10 . History significant lymphatic drainage problem 11 . History cancer require lymph node biopsy dissection 12 . Suffering significant skin condition treat area inflammatory skin condition , include , limited , open laceration abrasion , hidradenitis , dermatitis treatment area prior treatment ( duration resolution per Investigator 's discretion ) treatment course 13 . History keloid scarring , abnormal wound heal / prone bruise 14 . History epidermal dermal disorder ( particularly involve collagen microvascularity ) , include collagen vascular disease vasculitic disorder 15 . Use isotretinoin ( Accutane® ) within 6 month treatment study 16 . Subject systemic corticosteroid therapy 6 month prior throughout course study 17 . Dysplastic nevi area treat 18 . Participation study another device drug within 3 month prior enrollment study , treatment cellulite involved 19 . Subject palpable lymphadenopathy visit . Standard palpation technique use 20 . Subjects history severe edema 21 . As per Investigator 's discretion , physical mental condition might make unsafe subject participate study</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>